《七条措施》明确，要有效拓宽地企合作渠道，加快构建帮扶国有企业和受扶县合作共赢平台， 进一步推动公司注册落地受扶县。目前，仅四川发展（控股）公司，就已在白玉县成立藏医药公 司、甘孜州长江江源林业有限责任公司、甘孜州西南联交所企业服务有限公司3家子公司。其中， 企业服务公司为县域各类要素交易提供"一站式"解决方案，目前已完成今年帮扶产值目标；林业 公司积极争取政策资金，落地建设项目，各项工作正在有序推进。 《七条措施》还在原有结对帮扶关系基础上，明确对12个重点县域再增派1户省属或市属重要骨干 国有企业作为结对帮扶国有企业，并增加若干家与受扶县资源匹配度高、产业发展协同性强的国 有企业组成"矩阵式"帮扶团队，形成国有企业帮扶联合体。同时，要加大公益帮扶投入力度。 □四川日报全媒体记者 文露敏 在12月11日举行的白玉特色资源大健康产品合作研发签约活动上，白玉川发藏医药产业有限公司 与国内民族医药头部企业签约，双方将在藏医药原料种植，大健康产品研发、生产和销售等方面 建立全产业链合作，推动中藏药材走出大山，走向市场。 白玉川发藏医药产业有限公司是四川发展（控股）公司下属四川生物医药集团在甘孜州白玉县新 成立的企业 ...

针对Telix Pharmaceuticals Ltd的集体诉讼通知 - 罗森律师事务所提醒在2025年2月21日至2025年8月28日期间购买Telix Pharmaceuticals Ltd证券的投资者注意2026年1月9日的首席原告截止日期 [1] - 投资者可能有权通过风险代理收费安排获得赔偿而无需支付任何自付费用 [2] - 投资者可通过指定网站或电话联系以加入集体诉讼或申请担任首席原告 [3][6] 罗森律师事务所背景 - 该律所专注于证券集体诉讼和股东衍生诉讼在全球代表投资者 [4] - 该律所曾达成针对中国公司的史上最大证券集体诉讼和解并在2017年因和解数量被ISS证券集体诉讼服务评为第一自2013年以来每年排名前四 [4] - 该律所已为投资者挽回数亿美元其中2019年单年为投资者确保了超过4.38亿美元 [4] 诉讼指控详情 - 指控被告在集体诉讼期间做出了重大虚假和/或误导性陈述和/或未能披露相关信息 [5] - 具体指控包括被告在Telix前列腺癌治疗候选药物的进展方面存在重大夸大 [5] - 具体指控包括被告在Telix供应链及合作伙伴的质量方面存在重大夸大 [5] - 指控结果导致被告关于Telix业务运营和前景的陈述在所有相关时间均存在重大虚假和误导性和/或缺乏合理依据 [5]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) shared interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).The Phase 1/2 study evaluated 0.5 mg and 0.75 mg of MRT-2359 administered orally on a 21-days-on, 7-day-off drug schedule in combination with Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc.’s (OTC:ALPMF) (OTC:ALPMY) Xtandi (enzalutamide).The study population, as ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.GLP-1 pills for obesity are closer than ever. 2026 is likely the year that two new oral weight loss drugs will reach patients in the U.S. For some people, pills may serve as a more convenient – and potentially in certain cases cheaper – alternative to today's blockbuster injections.Drugmakers Novo Nordisk and Eli Lilly have ...

Pfizer has set its FY2026 profit forecast below analyst estimates, blaming projected losses on waning Covid vaccine sales and the looming patent cliff faced by some of its best-selling assets. Through this adjustment, Pfizer now expects profits ranging between $2.80 and $3 per share in 2026, which sits below the analyst estimate of $3.05 per share, as per the London Stock Exchange (LSEG). This means the company now expects its FY2026 revenue to fall somewhere between $59.5bn and $62.5bn. This compares w ...

Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.Upstart biotech company Viking Therapeutics (VKTX 1.27%) is a potential takeover candidate in 2026. That's not a reason to buy the stock in itself, but does highlight the potential value in its product pipeline. Here's why major drugmakers might now be drawn to buying this relatively small player in the pharmaceutical industry.Takeover activity is high in the industryThe recent bidding war between Pfi ...

Fizer falling after announcing its 2026 guidance. Our Anakica Kim Constantino has some details as the market didn't appreciate much what we got for the new year. Anakah, >> that's right, Carl.So, Fiser today issuing a modest 2026 guidance saying it expects sales to come in between 59.5% billion to 62.5% billion. And that's roughly in line with the street, but largely flat compared to the 62 billion in sales that expects for 2025. And in terms of its profit guidance, it came in slightly below what the street ...

Donovan Jones is an IPO research specialist with 15 years of experience identifying opportunities for high quality IPOs.He also leads the investing group IPO Edge, which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates. Learn moreAnaly ...

By STAN CHOE, AP Business WriterNEW YORK (AP) — The U.S. stock market is slipping on Tuesday following mixed data on the economy’s strength, which did little to clear uncertainty about where interest rates may be heading. The S&P 500 fell 0.6% in afternoon trading and remains a bit below its all-time high set last week. The Dow Jones Industrial Average was down 342 points, or 0.7%, as of 12:45 p.m. Eastern time, and the Nasdaq composite was 0.3% lower.Treasury yields eased a bit, following a larger initial ...